FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2567622012> ?p ?o ?g. }

• W2567622012 abstract "Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) with poor clinical outcomes and limited therapeutic options. To date, efforts to implement targetted therapy in TNBC have had limited success. Cumulative evidence suggest that cancer stem cells (CSCs) drive resistance to therapy, tumor recurrence, and may play a determinant role in the aggressive biology of TNBC. Recent studies indicate that CSCs are in reciprocal interaction with tumor microenvironment through cytokine-mediated signaling pathways. IL-6 is emerging as an important mediator of tumor growth and CSC survival. IL-6 is the most studied ligand of the gp130 receptor, which is a potent activator of the JAK/STAT3 signaling pathway important in survival and proliferation. The gp130 receptor is emerging as a promising target for cancer therapy. SC144 is a novel first-in-class gp130 inhibitor that has shown preclinical efficacy in ovarian cancer models. This study explores the effect of gp130 inhibition with SC144 on TNBC preclinical models. Methods: SC144 was provided by Dr. Neamati9s laboratory currently at the University of Michigan. We conducted in vitro studies using well-characterized human BC cell lines with a triple-negative phenotype. The effect of the novel compound SC144 on TNBC cell lines was evaluated using MTT assays for growth inhibition, ALDEFLUOR assay for identification of CSCs, ELISA tests for cytokine levels, and qRT-PCR for gene expression analysis. Results: SC144 inhibits cell growth in the TNBC cell lines SUM159, SUM149, MDAMB231, and HCC38 with IC50 values in a submicromolar range (0.87+0.17 μmol/L, 0.9+0.1 μmol/L, 0.5 μmol/L, 0.4 μmol/L, respectively). In an in vitro culture system of the TNBC cell line SUM159, docetaxel treatment induces a three-fold increase in IL-6 levels by ELISA and increases the CSC population measured by ALDEFLUOR. Pretreatment of SUM159 cells with SC144 significantly sensitized cells to docetaxel. Treatment of SUM159 cells with SC144 in addition to docetaxel significantly reduced the ALDH+ population measured by ALDEFLUOR compared to docetaxel alone (7.79+1% vs 22.23+5%). Investigating the potential effect of SC144 on the CSC population, we found a higher expression level of the IL-6 receptor in ALDH+ cells compared to ALDH- and the bulk population. Furthermore, in SUM159 cells treated with SC144 vs. control for 24 hours we found a significant decrease on expression of genes with documented relevance in CSC maintenance including CD44 (0.08 vs. 0.13), ALDH1a1 (0.001 vs. 0.006), STAT1 (0.004 vs. 0.024) and STAT3 (0.003 vs. 0.014). The in vivo study to test the efficacy of SC144 in a SUM159 xenograft model is undergoing. Conclusions: SC144, a novel gp130 inhibitor, has antitumor activity in human BC cell lines with the triple-negative phenotype. SC144 sensitizes cells to docetaxel therapy, and demonstrates an inhibitory effect on the CSC subpopulation. These findings identify a potential therapeutic target for TNBC. Citation Format: Leonel F. Hernandez-Aya, Yajing Liu, Kelsey Kerr, Shuzo Tamura, Nouri Neamati, Max S. Wicha, Monika L. Burness. Targeting the gp130 receptor in preclinical models of triple-negative breast cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4454. doi:10.1158/1538-7445.AM2015-4454" @default.
• W2567622012 created "2017-01-06" @default.
• W2567622012 creator A5005215978 @default.
• W2567622012 creator A5009005773 @default.
• W2567622012 creator A5014787907 @default.
• W2567622012 creator A5023220693 @default.
• W2567622012 creator A5059956218 @default.
• W2567622012 creator A5066453531 @default.
• W2567622012 creator A5089182718 @default.
• W2567622012 date "2015-08-01" @default.
• W2567622012 modified "2023-09-22" @default.
• W2567622012 title "Abstract 4454: Targeting the gp130 receptor in preclinical models of triple-negative breast cancer" @default.
• W2567622012 doi "https://doi.org/10.1158/1538-7445.am2015-4454" @default.
• W2567622012 hasPublicationYear "2015" @default.
• W2567622012 type Work @default.
• W2567622012 sameAs 2567622012 @default.
• W2567622012 citedByCount "0" @default.
• W2567622012 crossrefType "proceedings-article" @default.
• W2567622012 hasAuthorship W2567622012A5005215978 @default.
• W2567622012 hasAuthorship W2567622012A5009005773 @default.
• W2567622012 hasAuthorship W2567622012A5014787907 @default.
• W2567622012 hasAuthorship W2567622012A5023220693 @default.
• W2567622012 hasAuthorship W2567622012A5059956218 @default.
• W2567622012 hasAuthorship W2567622012A5066453531 @default.
• W2567622012 hasAuthorship W2567622012A5089182718 @default.
• W2567622012 hasConcept C121608353 @default.
• W2567622012 hasConcept C126322002 @default.
• W2567622012 hasConcept C143998085 @default.
• W2567622012 hasConcept C203014093 @default.
• W2567622012 hasConcept C2776107976 @default.
• W2567622012 hasConcept C2780110267 @default.
• W2567622012 hasConcept C502942594 @default.
• W2567622012 hasConcept C530470458 @default.
• W2567622012 hasConcept C55427017 @default.
• W2567622012 hasConcept C71924100 @default.
• W2567622012 hasConcept C86803240 @default.
• W2567622012 hasConceptScore W2567622012C121608353 @default.
• W2567622012 hasConceptScore W2567622012C126322002 @default.
• W2567622012 hasConceptScore W2567622012C143998085 @default.
• W2567622012 hasConceptScore W2567622012C203014093 @default.
• W2567622012 hasConceptScore W2567622012C2776107976 @default.
• W2567622012 hasConceptScore W2567622012C2780110267 @default.
• W2567622012 hasConceptScore W2567622012C502942594 @default.
• W2567622012 hasConceptScore W2567622012C530470458 @default.
• W2567622012 hasConceptScore W2567622012C55427017 @default.
• W2567622012 hasConceptScore W2567622012C71924100 @default.
• W2567622012 hasConceptScore W2567622012C86803240 @default.
• W2567622012 hasLocation W25676220121 @default.
• W2567622012 hasOpenAccess W2567622012 @default.
• W2567622012 hasPrimaryLocation W25676220121 @default.
• W2567622012 hasRelatedWork W1596890137 @default.
• W2567622012 hasRelatedWork W1769069832 @default.
• W2567622012 hasRelatedWork W2037535832 @default.
• W2567622012 hasRelatedWork W2214492077 @default.
• W2567622012 hasRelatedWork W2312605025 @default.
• W2567622012 hasRelatedWork W2331345300 @default.
• W2567622012 hasRelatedWork W2397108424 @default.
• W2567622012 hasRelatedWork W2397399954 @default.
• W2567622012 hasRelatedWork W2398963173 @default.
• W2567622012 hasRelatedWork W2404711667 @default.
• W2567622012 hasRelatedWork W2407602054 @default.
• W2567622012 hasRelatedWork W2741142739 @default.
• W2567622012 hasRelatedWork W2885963795 @default.
• W2567622012 hasRelatedWork W2886422276 @default.
• W2567622012 hasRelatedWork W2887509926 @default.
• W2567622012 hasRelatedWork W2944780155 @default.
• W2567622012 hasRelatedWork W2966796137 @default.
• W2567622012 hasRelatedWork W3013380505 @default.
• W2567622012 hasRelatedWork W3013616879 @default.
• W2567622012 hasRelatedWork W3013823763 @default.
• W2567622012 isParatext "false" @default.
• W2567622012 isRetracted "false" @default.
• W2567622012 magId "2567622012" @default.
• W2567622012 workType "article" @default.